<DOC>
	<DOCNO>NCT01403233</DOCNO>
	<brief_summary>The purpose study examine bioavailability cogniVida™ 10 healthy male subject consumption two different dos cogniVida™ ( 50 mg 100 mg ) compare plasma value value obtain subject receive rebaudioside A ( 303.68 mg ) . In addition , also safety tolerability parameter 24 hour ingestion study compound determine . cogniVida™ consider dietary supplement , therefore approve drug Food Drug Administration ( FDA ) . It regulate like food . The U.S. Food Drug Administration strictly regulate herb dietary supplement . The investigator claim supplement meant treat ailment .</brief_summary>
	<brief_title>Bioavailability Two Doses cogniVida™ With One Dose Rebaudioside A Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Sex : Male , age 30 50 year Subject willing maintain habitual diet physical activity pattern throughout study period . Subject health condition would prevent him/her fulfil study requirement judge Investigator basis medical history routine laboratory test result Subject body mass index ( BMI ) ≥20.00 &lt; 28.00 kg/m2 screening . Subject willing refrain consume drink contain grapefruit 7 day prior test day . Subject willing refrain consume caffeine , caffeinecontaining product alcoholic drink 24 h prior test day end assessment period . Subject willing refrain vigorous physical activity 12 h prior test day . Subject understands study procedure sign form provide informed consent participate study authorization release relevant protect health information study Investigator . Subject positive drug screen amphetamine , barbiturate , benzodiazepine , cannabis , cocaine , methamphetamine , methadone , 3,4methylenedioxymethamphetamine , opiates tricyclic antidepressant screen . Subjects positive blood alcohol breath carbon monoxide test screen . Subject abnormal laboratory test result clinical significance , include , limited : EpidermalGrowthFactorReceptor ( eGFR ) &lt; 60mL/min/1.73m2 , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥1.5X upper limit normal screening . Subject donate 300 mL blood lose significant amount blood three month prior screen . Anemia etiology define hemoglobin &lt; 140g/L male &lt; 123g/L female Subject uncontrolled hypertension ( systolic blood pressure ≥140 mm Hg diastolic blood pressure ≥90 mm Hg ) define average blood pressure measure screening . Subject history presence cardiac , renal , hepatic , endocrine ( include diabetes mellitus ) , pulmonary , biliary , gastrointestinal , pancreatic , neurologic disorder . Subject history , judgment Investigator , psychological illness condition interfere subject 's ability understand requirement study . Subject history presence cancer prior five year , except nonmelanoma skin cancer . Excessive habitual caffeine consumption ( &gt; 300 mg caffeine/d ≥ 3 cup caffeinated coffee/d ) , follow screen throughout study period . Use antibiotic sign active systemic infection . Treatment visit reschedule allow subject wash antibiotic least one month prior test visit . Use dietary supplement contain following : ginkgo biloba , St. John 's wort , ginseng , gotu kola ( Indian pennywort ) ; daily dos vitamin E ( ≥30 mg/d ) folic acid ( ≥400 ug/d ) ; thiamine , riboflavin , and/or pyridoxine ( ≥2 mg/d ) ; eicosapentaenoic acid ( EPA ) , docosahexaenoic acid ( DHA ) combination EPA + DHA ( ≥500 mg/d ) within 2 week prior screen . Consumption stevia extract ( reb A / steviosides ) sweeten products/drinks stevia leave within one month study . Subject exposure nonregistered drug product within 30 day prior screen visit . Recent history ( within 12 month screen visit ) strong potential alcohol substance abuse . Alcohol abuse define &gt; 14 drink per week ( 1 drink = 12 oz beer , 5 oz wine , 1½ oz distil spirit ) . Subject know allergy sensitivity study product ingredient study product meal provide .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
</DOC>